The findings unequivocally link the improved outcome of chemotherapy in the absence of myeloid cell-derived VEGF-A to sufficient release of the chemoattractant chemerin by the endothelium, which locally activates NK cell-based antitumour defenses and prevents chemotherapy-exacerbated cachexia at the systemic level (graphical summary, Fig. 7). This evidence concerns the gene RARRES2 and Cachexia.